| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.083 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.042 | 0.6 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |